Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAV Regimen in Relapsed/Refractory AML
NCT06434662Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Composite Complete Remission Rate. Started Feb 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06434662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434662.